Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Value Growth And Long-Term Outlook
The asthma and chronic obstructive pulmonary disease (copd) drugs market size has demonstrated significant growth in recent years. This market is projected to expand from $35.66 billion in 2025 to $39.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. The historical expansion can be attributed to factors such as rising smoking prevalence, urban air pollution, enhanced hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnoses.
The asthma and chronic obstructive pulmonary disease (copd) drugs market size is projected for substantial expansion over the coming years, anticipated to reach $55.67 billion in 2030, driven by a compound annual growth rate (CAGR) of 9.3%. This expected growth throughout the forecast period is attributable to factors like biologic drug innovation, an aging population, deteriorating air quality, developments in personalized respiratory medicine, and the emergence of homecare respiratory solutions. Significant trends during this period include a rising adoption of combination inhaler therapies, increased use of long-acting bronchodilators, the expansion of biologic treatments for severe asthma, a shift towards home-based respiratory management, and a growing demand for generic inhalation drugs.
Get A Free Sample Report With In-Depth Market Insights:
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Backed By Core Demand Fundamentals
The rising incidence of smoking is anticipated to fuel the expansion of the asthma and COPD drugs market in the future. Smoking involves the practice of using tobacco items by inhaling their smoke, potentially leading to severe health problems such as lung cancer and heart disease. The growing occurrence of smoking is primarily fueled by social factors, wherein peer pressure, cultural standards, and social surroundings encourage individuals to begin and persist in smoking. Asthma and chronic obstructive pulmonary disease (COPD) drugs play a role in lessening the respiratory harm caused by smoking through mechanisms like reducing inflammation, relaxing airway muscles, and enhancing airflow, thereby alleviating symptoms and improving lung function. As an illustration, a 2024 study on smoking patterns among young individuals, conducted by the European Respiratory Society’s (ERS), a Switzerland-based non-profit body, revealed a significant surge in smoking rates, climbing from 22.5% of participants in 2022 to 40.1% in 2024. Consequently, the increasing prevalence of smoking is propelling the growth of the asthma and COPD drugs market.
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segments: Where Is Growth Concentrated?
The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations
3) By Patient Group: Adult, Pediatric, Geriatric
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the asthma and chronic obstructive pulmonary disease (COPD) drugs market are increasingly prioritizing the integration of cutting-edge drug-combination therapies, such as rescue inhalers that combine short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS). This strategic focus aims to deliver enhanced patient outcomes, including the prevention of severe asthma attacks, more effective inflammation management, and improved overall disease control. A SABA–ICS rescue inhaler functions by merging a short-acting beta-agonist, which provides rapid relief by relaxing airway muscles, with an inhaled corticosteroid, which targets and reduces chronic airway inflammation. This combination offers a dual advantage, delivering both immediate symptom alleviation and crucial anti-inflammatory effects. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, introduced AIRSUPRA (albuterol/budesonide) into the US market. This fixed-dose SABA-ICS rescue inhaler is engineered to alleviate asthma symptoms and preempt sudden severe respiratory distress, leveraging its dual-component formula delivered through pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA contributes to superior acute symptom relief while concurrently tackling airway inflammation, thereby lowering the likelihood of severe asthma exacerbations and promoting enhanced asthma management.
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Key Participants And Competitive Landscape
Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.
View The Full Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model